217 related articles for article (PubMed ID: 28727815)
1. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Pascual T; Apellániz-Ruiz M; Pernaut C; Cueto-Felgueroso C; Villalba P; Álvarez C; Manso L; Inglada-Pérez L; Robledo M; Rodríguez-Antona C; Ciruelos E
PLoS One; 2017; 12(7):e0180192. PubMed ID: 28727815
[TBL] [Abstract][Full Text] [Related]
2. Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.
Fukudo M; Ishibashi K; Kitada M
Invest New Drugs; 2021 Dec; 39(6):1707-1715. PubMed ID: 34041638
[TBL] [Abstract][Full Text] [Related]
3. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
4. Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients.
Bonnet S; Falkowski S; Deppenweiler M; Monchaud C; Arnion H; Picard N; Woillard JB
Pharmacogenomics J; 2020 Oct; 20(5):647-654. PubMed ID: 32015456
[TBL] [Abstract][Full Text] [Related]
5. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
Ng VC; Johnson JJ; Cuellar S
J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
[TBL] [Abstract][Full Text] [Related]
6. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites.
Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
Clin Ther; 2016 Apr; 38(4):905-17. PubMed ID: 26947172
[TBL] [Abstract][Full Text] [Related]
8. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
Hao Y; Lin PL; Xie J; Li N; Koo V; Ohashi E; Wu EQ; Rogerio J
J Comp Eff Res; 2015 Aug; 4(4):315-26. PubMed ID: 26274793
[TBL] [Abstract][Full Text] [Related]
11. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
13. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Moscetti L; Vici P; Gamucci T; Natoli C; Cortesi E; Marchetti P; Santini D; Giuliani R; Sperduti I; Mauri M; Pizzuti L; Mancini ML; Fabbri MA; Magri V; Iezzi L; Sini V; D'Onofrio L; Mentuccia L; Vaccaro A; Ramponi S; Roma CL; Ruggeri EM
Breast; 2016 Oct; 29():96-101. PubMed ID: 27476084
[TBL] [Abstract][Full Text] [Related]
14. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
15. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Hortobagyi GN; Chen D; Piccart M; Rugo HS; Burris HA; Pritchard KI; Campone M; Noguchi S; Perez AT; Deleu I; Shtivelband M; Masuda N; Dakhil S; Anderson I; Robinson DM; He W; Garg A; McDonald ER; Bitter H; Huang A; Taran T; Bachelot T; Lebrun F; Lebwohl D; Baselga J
J Clin Oncol; 2016 Feb; 34(5):419-26. PubMed ID: 26503204
[TBL] [Abstract][Full Text] [Related]
16. [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
Jerusalem G; Rorive A; Collignon J
Rev Med Liege; 2014 Sep; 69(9):510-7. PubMed ID: 25796760
[TBL] [Abstract][Full Text] [Related]
17. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
Vernieri C; Nichetti F; Lalli L; Moscetti L; Giorgi CA; Griguolo G; Marra A; Randon G; Rea CG; Ligorio F; Scagnoli S; De Angelis C; Molinelli C; Fabbri A; Ferraro E; Trapani D; Milani A; Agostinetto E; Bernocchi O; Catania G; Vantaggiato A; Palleschi M; Moretti A; Basile D; Cinausero M; Ajazi A; Castagnoli L; Lo Vullo S; Gerratana L; Puglisi F; La Verde N; Arpino G; Rocca A; Ciccarese M; Pedersini R; Fabi A; Generali D; Losurdo A; Montemurro F; Curigliano G; Del Mastro L; Michelotti A; Cortesi E; Guarneri V; Pruneri G; Mariani L; de Braud F
Clin Cancer Res; 2021 Jun; 27(12):3443-3455. PubMed ID: 33785482
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in heavily pretreated metastatic breast cancer: Is real world experience different?
Bajpai J; Ramaswamy A; Gupta S; Ghosh J; Gulia S
Indian J Cancer; 2016; 53(3):464-467. PubMed ID: 28244487
[TBL] [Abstract][Full Text] [Related]
19. Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.
Mo H; Renna CE; Moore HCF; Abraham J; Kruse ML; Montero AJ; LeGrand SB; Wang L; Budd GT
Clin Breast Cancer; 2022 Feb; 22(2):143-148. PubMed ID: 34740541
[TBL] [Abstract][Full Text] [Related]
20. [Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
Ito Y; Masuda N; Iwata H; Mukai H; Horiguchi J; Tokuda Y; Kuroi K; Mori A; Ohno N; Noguchi S
Gan To Kagaku Ryoho; 2015 Jan; 42(1):67-75. PubMed ID: 25596682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
